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 Introduction 
 Henoch-Schönlein purpura (HSP) is a 
systemic small vessel leucocytoclastic vas-
culitis characterized by vascular deposi-
tion of IgA immune complexes. It mostly 
affects children, being the most common 
vasculitis of childhood with 50% of all cas-
es occurring before the age of 5 years  [1] . 
The exact pathogenesis of serum IgA im-
mune-complex-level dysregulation re-
mains unknown; however, group A strep-
tococcal tonsillitis/pharyngitis and un-
specific upper airway infections are the 
most common triggering factors  [2] . HSP 
has also been reported to appear in asso-
ciation with malignancy, mostly with solid 
tumors but also in the setting of plasma 
cell dyscrasias like multiple myeloma  [3–
7] , and also as a first manifestation of my-
eloma  [5–7] . The disease typically presents 
with a classic palpable purpura, mostly in-
volving the lower extremities, due to eryth-
rocyte extravasation into the skin. Polyar-
thralgia, usually of the knees and ankles, 
is present in more than 80% of patients  [1] . 
More than half of the patients have colicky 
abdominal pain, which can be associated 
with mild bloody diarrhea. The most 
feared feature of HSP is glomerulonephri-
tis (IgA nephropathy), occurring in 40–
50% of patients and manifesting in most 
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 Abstract 
 Adult-onset Henoch-Schönlein purpura 
(HSP) tends to become chronic-relapsing, 
yet rarely leads to organ impairment, e.g. 
due to chronic glomerulonephritis. Bed rest, 
compression and nonsteroidal anti-inflam-
matory drugs are usually sufficient to con-
trol the active phases. We report 2 cases of 
adult HSP with an unusually severe evolu-
tion. One patient required intensive-care 
treatment for hypovolemic shock caused by 
hemorrhagic pancolitis; the other had pro-
gressive and extremely extensive vasculitic 
leg ulcers. Both were refractory to common 
immunosuppression with systemic cortico-
steroids (oral and pulse) and additive ste-
roid-sparing immunosuppressive drugs. 
Only after the introduction of plasmaphe-
resis did both patients show a dramatic im-
provement in the disease, with rapid and al-
most complete healing. Plasmapheresis is a 
rarely used therapeutic tool in the treatment 
of severe HSP, but the growing literature on 
its highly beneficial effect underlines its po-
tential usefulness. 
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cases as proteinuria, microhematuria and 
erythrocyte casts. Nephropathy represents 
the most common cause of morbidity and 
death related to HSP, with 12–19% of chil-
dren progressing to transient renal failure 
and up to 3% to chronic end-stage renal 
disease  [8, 9] . Other rare complications in-
clude central nervous system vasculitis, 
orchitis, and cardiac and ophthalmologi-
cal involvement  [10] .
 HSP usually has a spontaneous self-
limiting favorable evolution, with up to 
95% of affected patients showing a com-
plete remission within a few weeks. The 
overall prognosis is excellent, even with 
one third to one half of patients having 1 
or more recurrences of symptoms (usually 
within 6 weeks, but also as late as 3–7 
years) afterwards  [11] .
 Clinical manifestations in adult-onset 
HSP tend to be more pronounced and re-
currences are more frequent. In rare cases, 
HSP can become organ-compromising or 
even life-threatening. The 2 reported cases 
are good examples of refractory or even 
life-threatening HSP, for whom systemic 
corticosteroids, both oral and intravenous 
pulse, and steroid-sparing agents did not 
stabilize the disease. Eventually, plasma-
pheresis led to a rapid and long-lasting re-
mission in both patients.
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 Case Reports 
 Patient 1 
 A 44-year-old woman first presented in 
August 2006 with classical palpable pur-
pura involving her distal legs and arms. 
Two months later she complained of dif-
fuse and painful joint swelling of her 
knees, ankles, elbows, and wrists. In De-
cember 2006, new crops of palpable pur-
pura started to appear around both ankles. 
The skin lesions were highly exudative, 
leading to pustulation and rapid formation 
of deep and painful polycyclic skin ulcers 
that continued to extend over the whole 
circumference and length of legs ( fig. 1 ).
 Skin biopsies showed small vessel vas-
culitis with vascular IgA deposits on direct 
immunofluorescence, with no significant 
histological signs of thrombosis. Hematol-
ogy showed normocytic anemia (11.2 g/dl) 
and leukocytosis (10.3 g/l with normal dif-
ferentiation). Urine analysis evidenced 
light hematuria but no proteinuria, and 
creatinine clearance was in the normal 
range. An elevated IgA level was found on 
immunoserology, and protein electropho-
resis detected a monoclonal IgA gammop-
athy. The cryoglobulin test was negative. A 
diagnosis of HSP in the presence of mono-
clonal IgA gammopathy in the setting of a 
plasma cell dyscrasia (hematologically at 
the current moment, no further specifica-
tion), without renal function impairment, 
was made.
 In May 2007, corticosteroid-based im-
munosuppression was started with oral 
prednisone 1 mg/kg/day, together with 
azathioprine 1.5 mg/kg/day as the steroid-
sparing agent. The skin ulcerations con-
tinued to extend under this well-controlled 
immunosuppression. Intravenous methyl-
prednisolone pulse therapy with 1.0 g i.v. 
methylprednisolone on the 3 following 
days, over 3 consecutive months (Novem-
ber 2007 to January 2008) did not show 
any positive effect either. Meanwhile, the 
skin lesions had become debilitating. 
 In February 2008, plasma exchange 
therapy (plasmapheresis) was started, and 
9 sessions over 15 days were scheduled. Al-
ready after 5 sessions, all skin ulcerations 
showed a dramatic improvement with 
abundant granulation and rapid re-epithe-
lization from the wound borders ( fig. 2 ). 
Local wound care was kept simple and 
comprised exclusively chlorhexidine-em-
bedded fatty gauze. The wounds contin-
ued to improve and to heal completely un-
der oral prednisone (0.4 mg/kg/day) and 
azathioprine (2 mg/kg/day). After discon-
tinuation of plasmapheresis, the patient 
experienced a disease reactivation mani-
festing as palpable purpura and correlat-
ing with recurrent detectable serum para-
protein, which required further plasma 
exchange sessions. Again, recovery was 
rapid and complete.
 Patient 2 
 In August 2007, a 28-year-old woman 
began to complain of swollen ankle joints 
and arthralgia, and 2 days later showed 
palpable purpuric skin lesions on both legs 
and thighs. Hematology, C-reactive pro-
tein, hepatic and renal serum parameters, 
immunological screening tests, and com-
plete urine analysis were all within normal 
ranges. Bacteriological culture of a throat 
swab did not indicate the presence of group 
A streptococci.  After dermatohistopatho-
logical confirmation of cutaneous small 
vessel leukocytoclastic vasculitis with dis-
crete vascular IgA deposits on direct im-
munofluorescence, a diagnosis of HSP was 
made.
 The course was refractory to oral pred-
nisone at 1 mg/kg/day, and after 1 week the 
patient required hospitalization. Treat-
ment was continued on the same dose of 
prednisone, with bed rest and compres-
sion treatment of the legs. The local symp-
toms continued to be refractory and at the 
third day of inpatient treatment (15 days 
after the first consultation) the patient de-
veloped acute and profuse hematemesis 
 Fig. 1. Patient 1: presentation at first dermatological evaluation, 
with deep and painful polycyclic skin ulcers over the whole cir-
cumference and length of the left leg. 
 Fig. 2. Patient 1: abundant granulation and re-epithelization in all 
wounds after 5 plasma exchange sessions. 
 Fig. 3. Patient 2: endoscopic image show-
ing serious hemorrhagic duodenitis. 
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and melena, which led to hypovolemic 
shock within a few hours. The patient was 
stabilized and transferred to the intensive-
care unit. Gastroscopic images showed a 
serious hemorrhagic duodenitis ( fig. 3 ), 
while colonoscopy showed hemorrhagic 
colitis and terminal ileitis. Histologies 
provided evidence of exclusively necrotic 
colon mucosa, but no vasculitic lesions. 
Abdominal contrast computed tomogra-
phy showed a pan-enterocolitis, but no ev-
idence of mesenterial artery obstructions.
 She was put on intravenous methyl-
prednisolone pulse therapy (1.0 g i.v. meth-
ylprednisolone for the 3 following days); 
however, the pancolitis did not respond 
sufficiently. After insufficient response 
under high-dose oral corticosteroids for a 
further 10 days, the patient was started on 
plasma exchange treatment (plasmapher-
esis, 6 plasma exchanges in 10 days), lead-
ing to a rapid and long-lasting remission. 
Oral corticosteroids were continued at 
0.25 mg/kg/day and azathioprine at 2.5 
mg/kg/day. At present, the patient remains 
stable.
 Discussion 
 Plasmapheresis is an extracorporeal 
blood purification technique that was de-
veloped in the late 1970s. Its effect is based 
on the removal of large molecular weight 
molecules (e.g. immunoglobulins and im-
mune complexes, paraprotein, undefined 
autoantibodies, pro-inflammatory cyto-
kines, complement factors, lipoproteins, 
toxins) from the patient’s plasma and sub-
stitution with other fluids  [12] (fresh fro-
zen plasma, albumin or saline solution, 
depending on indication and comorbidi-
ties). Usually, at least 5 separate exchanges 
over 7–10 days are required to achieve the 
removal of 90% of the total initial immu-
noglobulin. Due to the highly probable 
pathogenic role of the monoclonal IgA 
component in HSP activity in patient 1, we 
considered plasmapheresis as a very prom-
ising solution. The prompt clinical im-
provement after therapy start confirmed 
our idea, and was probably due to the elim-
ination of circulating IgA.
 According to the American Associa-
tion of Blood Banks  [13] , plasmapheresis is 
recognized as standard therapy (category 
I) for several autoimmune diseases includ-
ing acute and chronic inflammatory poly-
radiculoneuropathy, Goodpasture’s syn-
drome, Guillain-Barré syndrome, throm-
botic thrombocytopenic purpura and 
myasthenia gravis. It is also generally ac-
cepted in a supportive indication (category 
II, in association with other systemic treat-
ments) for rapidly progressive glomerulo-
nephritis and hyperviscosity syndrome in 
myeloma patients.
 Dermatological diseases that may ben-
efit from plasmapheresis are listed in cat-
egory III (relative indications) and com-
prise systemic lupus erythematosus, re-
fractory pemphigus vulgaris, systemic 
vasculitis, and severe forms of secondary 
Raynaud’s phenomenon  [14] .
 As an alternative to classic plasmapher-
esis, the double-filtration technique with-
out plasma replacement has also success-
fully been used in the treatment of HSP, 
especially in patients with crescentic glo-
merulonephritis and acute renal failure 
 [15] .
 A PubMed search revealed various sin-
gle case reports regarding plasmapheresis 
as a sole therapy  [16] or in combination 
with numerous other immunosuppressive 
drugs  [17–22] , including oral prednisone, 
intravenous methylprednisolone, azathio-
prine and cyclophosphamide. It is of par-
ticular interest to note the publication of 2 
cases of HSP with cerebral vasculitis  [16, 
22] and 2 cases of severe intestinal involve-
ment  [18, 21] , all responding promptly to 
plasma exchange. There are also some case 
series, the largest detailing about 16 chil-
dren treated between 1988 and 2005 with 
plasmapheresis monotherapy  [23] , show-
ing excellent results, as did a smaller series 
of 9 children  [24] . The same clinical im-
provement was observed in a series of 6 
Japanese children who were treated with a 
combination of plasmapheresis and mul-
tiple immunosuppressive drug therapy  [8] . 
The therapy regimens used in the publica-
tions listed here were quite heterogeneous 
and total plasma exchange sessions ranged 
from 4 to 12, extending over a time period 
of 2–6 weeks. 
 In conclusion, we can add 2 more cases 
of severe and complicated HSP, refractory 
to corticosteroids and azathioprine, in 
whom the introduction of plasmapheresis 
led to a rapid and long-lasting improve-
ment. The further interest of these cases 
lies in the life-threatening complications 
of patient 2, the extremely extensive skin 
necrosis of the legs in patient 1, and in the 
rare setting of HSP in plasma cell dyscrasia 
with monoclonal IgA gammopathy (pa-
tient 1), with very few cases having been 
reported in the literature  [3–7] . Plasma ex-
change rapidly and directly eliminates the 
circulating IgA immune complexes. A 
combination with classical immunosup-
pression should help to inhibit the ongoing 
production of immunoglobulin and pro-
inflammatory cytokines, and thus avoid 
relapses or rebound phenomenon after 
cessation of the plasma exchange therapy. 
At present, there are no comparative stud-
ies addressing this issue. The higher risk of 
short-term (infections, gastrointestinal 
disorders) and long-term (neoplasia, Cush-
ing syndrome) side effects related with 
prolonged and/or high-dose immunosup-
pressive drug therapy has to be balanced 
on an individual basis with the risk of con-
tinuing disease activity.
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